Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 10;23(1):242.
doi: 10.1186/s12933-024-02319-7.

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide

Fatemeh Taktaz  1 , Rosaria Anna Fontanella  1 , Lucia Scisciola  2 , Ada Pesapane  1 , Manuela Giovanna Basilicata  1 , Puja Ghosh  1 , Martina Franzese  1 , Giovanni Tortorella  1 , Armando Puocci  1 , Maria Teresa Vietri  3   4 , Annalisa Capuano  5 , Giuseppe Paolisso  1   6 , Michelangela Barbieri  1
Affiliations
Review

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide

Fatemeh Taktaz et al. Cardiovasc Diabetol. .

Abstract

Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead to weight loss, better glycemic control, and reduced cardiometabolic risk factors. GLP1 receptor agonists have been proven effective antidiabetic medications with possible cardiovascular benefits. Even though they have been proven to reduce the risk of major adverse cardiovascular events, their effectiveness in treating heart failure is unknown. Unlike traditional GLP1 receptor agonists, tirzepatide is more selective for the GIP receptor, resulting in a more balanced activation of these receptors. This review article discusses the possible mechanisms tirzepatide may use to improve cardiovascular health. That includes the anti-inflammatory effect, the ability to reduce cell death and promote autophagy, and also its indirect effects through blood pressure, obesity, and glucose/lipid metabolism. Additionally, tirzepatide may benefit atherosclerosis and lower the risk of major adverse cardiac events. Currently, clinical trials are underway to evaluate the safety and efficacy of tirzepatide in patients with heart failure. Overall, tirzepatide's dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, offering a potential new therapeutic option for treating cardiovascular diseases and heart failure.

Keywords: GIP receptor; GLP-1 receptor; GLP1 receptor agonists; Heart failure; Tirzepatide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Comprehensive picture of molecular and cellular interaction relevant to beneficial effect of tirzepatide in metabolic and cardiovascular disorders. It is signaling pathways associated with GIP and GLP1 receptors, as well as key molecules cAMP and PKA involved in cellular processes related to cardiovascular pathophysiology. The diagram highlights an in-depth understanding of the complex network of pathways that influence conditions like atherosclerotic, inflammatory response, and metabolic dysregulation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020, 5(17). - PMC - PubMed
    1. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8. doi: 10.1038/s41591-022-01707-4. - DOI - PMC - PubMed
    1. Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Griffin R, Stefanski A, Garvey WT. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024;26(1):319–28. doi: 10.1111/dom.15318. - DOI - PubMed
    1. Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and glucose-dependent Insulinotropic Polypeptide Dual Agonist. J Lipid Atheroscler. 2023;12(3):213–22. doi: 10.12997/jla.2023.12.3.213. - DOI - PMC - PubMed
    1. Min T, Bain SC. The role of Tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143–57. doi: 10.1007/s13300-020-00981-0. - DOI - PMC - PubMed

Publication types

MeSH terms